Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RxSight, Inc. - Common Stock (NQ: RXST )

33.66 -4.53 (-11.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about RxSight, Inc. - Common Stock

< Previous 1 2 3 Next >
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Forecasting The Future: 4 Analyst Projections For RxSight
Via Benzinga
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Analyst Scoreboard: 7 Ratings For RxSight
Via Benzinga
Peeling Back The Layers: Exploring RxSight Through Analyst Insights
Via Benzinga
Deep Dive Into RxSight Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
RxSight Analysts Slash Their Forecasts After Q2 Results
Via Benzinga
RXST Stock Earnings: RxSight Beats Revenue for Q2 2024
RXST stock results show that RxSight beat on revenue for the second quarter of 2024. 
Via InvestorPlace
RxSight Stock Sees Relative Strength Rating Rise To 91
On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91. 
Via Investor's Business Daily
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday! 
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
RxSight Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Why RxSight (RXST) Shares Are Falling
RxSight shares are trading lower by 5.6% during Thursday's session. The company announced pricing of its $100 million proposed public offering of common stock. 
Via Benzinga
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What 10 Analyst Ratings Have To Say About RxSight
Via Benzinga
Assessing RxSight: Insights From 8 Financial Analysts
Via Benzinga
Forecasting The Future: 9 Analyst Projections For RxSight
Via Benzinga
Do You Have Your Eye On Vision Care Stocks?
For investors seeking stable and growing opportunities, eye care stocks are an attractive option. 
Via Talk Markets
RXST Stock Earnings: RxSight Beats EPS, Beats Revenue for Q1 2024
RXST stock results show that RxSight beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Chart Of The Day: RxSight - Cashing In On Cataracts
Earnings are estimated to increase 33.30% this year, increase an additional 26.60% next year and continue to compound at an annual rate of 19.00% for the next 5 years 
Via Talk Markets
Recap: RxSight Q4 Earnings
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
RxSight's Earnings Outlook
Via Benzinga
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
Via Benzinga
The Analyst Landscape: 8 Takes On RxSight
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.